
October 27-29, 2020 | Digital Event 9.00AM - 5.30PM EDT | 6.00AM - 2.30PM PDT

www.protein-misfolding.com

BOOK BY JULY 31 TO SAVE UP TO \$600

Digital



Protein Misfolding Drug Discovery

Discover & Translate Disease-Modifying Therapeutics that Target Misfolded & Oligomeric Proteins to Transform Clinical Outcomes in Neurodegeneration & Beyond

Expert Speakers Include:



Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease AbbVie



Michele Vendruscolo Professor & CSO Cambridge University Centre for Misfolding Diseases & Wren Therapeutics



Rick Morimoto Professor Northwestern University





Aubin Michalon Principal Scientist Neurimmune

Neil Cashman

CSO & Co-Founder

ProMIS Neurosciences

dynamic

BIOSENSORS



StressMarg

Biosciences

Beth Hoffman Founder, President & CEO **Origami Therapeutics**



. . . .

Robert Scannevin

Yumanity

VP, Discovery Biology

Marcia Taylor VP Research & Neurodegeneration Alliance Manager Treventis



Wagner Zago CSO Prothena









Welcome to the Digital Protein Misfolding Drug Discovery Summit

With protein misfolding and aggregation prevalent in neurodegeneration, cancer, metabolic and ophthalmic diseases, this presents huge patient and product opportunity. However, decades of clinical lessons and revived investment in understanding the molecular biology of protein misfolding disorders, has failed to yield clinically meaningful therapies targeting misfolded or oligomeric proteins.

The **Digital Protein Misfolding Drug Discovery Summit** arrives as the definitive forum for large pharma, innovative biotech and research institutes to shift the drug discovery paradigm and seize the untapped opportunity of protein misfolding targeted therapeutics.

This Summit will unite drug discovery and development professionals to **validate novel misfolded and oligomeric protein targets underlying neurodegeneration and beyond, improve preclinical predictability of patient derived models, optimize drug pharmacology** and **accelerate the translation of novel protein misfolding targeted therapeutics**.

With numerous candidates poised to enter the clinic, join the **Digital Protein Misfolding Drug Discovery Summit - the only industry and translational focused conference**, dedicated to discover and translate disruptive disease-modifying therapeutics targeting misfolded and oligomeric proteins in neurodegeneration and beyond.

Why our speakers are so excited:

At last, a comprehensive industrial-academic meeting on treating protein misfolding diseases!

Neil Cashman, ProMIS Neurosciences

I am looking forward to the first event on drug discovery for protein misfolding diseases, which will bring together major players in this area. It will be a great opportunity for discussing and prioritizing targets and methods.

Michele Vendruscolo, Cambridge University & Wren Therapeutics

Why Attend the Digital Protein Misfolding Drug Discovery Summit?



Discover the latest understanding of different molecular approaches towards targeting protein misfolding with insights from **Prothena, Origami Therapeutics** & **Stanford University**



Overcome preclinical challenges for robust translation of protein misfolding therapeutic candidates into the clinic with insights from **AbbVie** & **Eli Lilly**



Understand different drug modalities such as immunotherapies, small molecules and peptide-based approaches to accelerate your candidates to clinic with insights from **ProMIS Neurosciences**, **CantaBio Pharmaceuticals & Aelin Therpaeutics**



Leverage crosslearnings from clinical case studies to successfully and robustly translate your drug candidates into different clinical indications with insights from **Anavex Life Sciences** & Lysosomal Therapeutics



Join the momentum to reverse the undruggable nature of misfolded proteins and aggregates with insights from **Yumanity & Wren Therapeutics**





YOUR EXPERT SPEAKERS



Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease AbbVie



John Hey CSO Alzheon



Christopher Missling President & CEO Anavex Life Sciences



Michele Vendruscolo Professor & CSO Cambridge University Centre for Misfolding Diseases & Wren Therapeutics



Gergely Tóth Founder & CEO CantaBio Pharmaceuticals



Behnam Nabet Postdoctoral Research Fellow, Gray Lab

Dana-Farber Cancer Institute



Ulrich Rant CEO Dynamic Biosensors



David Lynn HHMI Professor Emory University



Zhexing Wen Assistant Professor Emory University



Giulio Pasinetti Chair & Professor of Neurology Icahn School of Medicine at Mount Sinai



Peter Lansbury CSO Lysosomal Therapeutics



Aubin Michalon Principal Scientist Neurimmune



Rick Morimoto Professor Northwestern University



Beth Hoffman Founder, President & CEO Origami Therapeutics



Neil Cashman CSO & Co-Founder ProMIS Neurosciences

Wagner Zago CSO **Prothena**



Akinori Hishiya Founder & CSO **SOLA Biosciences**



Judith Frydman Professor Stanford University



Ariel Louwrier President & CEO StressMarq Biosciences Inc.



Marcia Taylor VP Research & Neurodegeneration Alliance Manager Treventis



David Smith Associate Professor West Virginia University



Johnny Habchi Head of Research Wren Therapeutics



Robert Scannevin VP, Discovery Biology Yumanity

We are dealing with extremely challenging diseases and this requires a joined-up approach to deliver very much needed solutions. It is the right time for everyone to come together and accelerate drug discovery for these debilitating diseases



+1 617 455 4188 info@hansonwade.com
www.protein-misfolding.com

An Interactive Online Experience

The Digital Protein Misfolding Drug Discovery Summit is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created the digital summit to satisfy the industry's need to share cutting-edge research, learn from your peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built digital event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

KEY FEATURES OF THE DIGITAL SUMMIT

Our mission remains dedicated to ensuring the protein misfolding community have the tools and the means to advance their research and knowledge of the field. Although we may not meet in person, we uphold our promise to unite the protein misfolding community.

Whilst face-to-face meetings are put on hold, we continue to deliver the key features of a physical meeting in an optimal digital world:



Delegate Profile

Set up personalized profiles to easily identify the name, job title and

company of other attendees



Stage Area Most presentations will be delivered in the 'stage' area, much like the main conference room onsite



Sessions Area

Smaller groups can get together in this breakout area for panel

discussions and other interactive sessions



Demo Area

Visit the virtual exhibition area to explore the solutions our

specialist vendors have on offer



Chat Rooms

Connect with your peers and start conversations with individuals or all

attendees in private and public chatrooms



Speed Networking

This virtual networking session will connect you with other attendees to

establish new industry contacts

WHAT CAN YOU EXPECT?



Live Q&A

4

Ask your questions directly to presenters in realtime, just as you would face-to-face. Make your voice heard and jump on the screen to share your thoughts



Audience Discussions

Interactive speed networking will allow you to meet and network with your peers. In addition, join our informal "meeting rooms" where up to 10 guests can join an interactive and informal chat.



Virtual Exhibition Hall

Take a tour around our virtual exhibition hall. Leading vendors will be waiting to show you how they can aid your disease modifying therapies into clinic. Easily exchange business cards to keep the conversation going!



Private Message Attendees

Grab an old colleague or a new connection and invite them to a personal meeting room. Using our bespoke chat function, you can see all attendees in real-time and invite them for a conversation





structurally and functionally variant protein aggregates

animal models, and human organoids.

· How do amyloid strains form and spread?

Topics to be covered:

amyloid strains?

therapeutics?

strains on brain functions?

report on pathobiology

and defining the cellular and biophysical parameters that underlie their function with different models including yeast,

• Are there common structural dynamics to proteopathic

• Are there cell type-specific impacts of amyloidogenic

· How can yeast, animal models, and human organoids

· How to translate pathobiology of amyloid strains for

• How is structure linked to Ab and tau phenotypes,

pathologies, and cross-seeding capabilities?

PRE-CONFERENCE WORKSHOP DAY TUESDAY | OCTOBER 27 9.30AM - 4.00PM EDT | 6.30AM - 1.00PM PDT

9.30 | 6.30 Online Registration & Virtual Coffee Networking

Workshop A

10.00 | 7.00

Leveraging Pathobiology of Self-Perpetuating Amyloid Strains for Translational Protein Misfolding Targeted Therapeutics

For most of the past 70 years of molecular biology, amino acid sequences encoded in genomic DNA and environmental context have been the primary consideration for functional protein folding. However, many proteins acquire alternative conformations and proceed through two-step nucleation to achieve paracrystalline variants that can faithfully reproduce, for example in case of selfperpetuating cross- β fibrils (amyloids). These amyloids are associated with more than 40 devastating diseases, including Alzheimer's disease and various systemic and localized amyloidoses. Recent evidence suggests that amyloids can exist as structural and functional variants called strains, but surprisingly little is known about the steps at which strain formation is controlled, the molecular mechanisms underlying strain patterns, or the role of polymorphic strains in pathogenicity. Our goal in the workshop will be to inform therapeutic strategies for amyloidoses by illuminating the dynamic nature of

Workshop Leaders

Workshop B



David Lynn HHMI Professor Emory University

12.30 | 9.30 Lunch & Virtual Speed Networking

1.30 | 10.30

Opportunities for Pharmacological Manipulation of the Ubiquitin Proteasome System from PROTACS to Proteasome Enhancement

Zhexing Wen

Assistant Professor

Emory University

Enabled by the exciting clinical progression of PROTACbased therapies, our understanding of the pharmacological opportunity held by the ubiquitin proteasome system has taken a giant leap in recent years. Still, our limited knowledge of fundamental biology and chemistry is hindering the ongoing efforts to translate robust candidates into the clinic. In this workshop, we will cover the vital technical scientific challenges that need to be addressed to accelerate successful PROTAC therapies through the clinic in the future. Also, we will discuss the opportunities and findings on targeting protein degradation using the latest PROTAC approaches. Topics to be covered:

- How can the ubiquitin system be cooped for targeted protein degradation?
- How can protein targeting chimeric molecule (PROTACS) be used to target specific proteins for degradation?
- · Can proteasome capacity be upregulated?
- Can ubiquitin dependant protein degradation be enhanced?
- How can degradation of intrinsically disordered proteins (IDPs) be stimulated?

Workshop Leaders



5

David Smith Associate Professor West Virginia University



Behnam Nabet Postdoctoral Research Fellow, Gray Lab Dana-Farber Cancer Institute

• +1 617 455 4188 @ info@hansonwade.com





CONFERENCE DAY ONE WEDNESDAY | OCTOBER 28

9.30AM - 4.00PM EDT | 6.30AM - 1.00PM PDT

	8.30 <mark>5.30</mark>	Online Registration & Virtual Networking
	8.55 <mark>5.55</mark>	Chairperson's Opening Remarks
Devel		ormation-Specific & Agnostic Therapeutics
	Against	Misfolded & Oligomeric Proteins
	9.00 <mark>6.00</mark>	Small Molecule Inhibitors of a Common Conformational Morphology Identified in Intrinsically Disordered Proteins
Marcia Taylor VP Research & Neurodegeneration Alliance Manager Treventis		 Common Conformational Morphology (CCM) acts as an in silico crystal structure for IDPs Hit identification has been performed for alpha synuclein, amylin, amyloid beta, and tau Demonstrated dose dependent decrease in oligomeric species of amyloid beta and tau
	9.30 <mark>6.30</mark>	Amyloid Removal Therapy for Systemic Amyloidosis
Aubin Michalon Principal Scientist Neurimmune		 Generation of amyloid selective antibodies from human immune memory repertoires Lead selection and PoC studies with focus on assays with high translational value Modeling treatment response to support clinical trial design
	10.00 7.00	Regulation of Proteostasis Networks in Aging & Disease
Rick Morimoto Professor Northwestern University		 Understanding how the proteostasis network is established in development to protect through reproduction and fails in adulthood and ageing Mapping out the course of events, including chaperone sequestration, that perpetuate protein aggregation and misfolding – what markers might be predictive of age-associated disease? Investigating the systemic consequence and communication of protein misfolding between tissues
	10.30 <mark>7.30</mark>	Exploring Conformational Changes and Multimerization of
Ulrich Rant CEO Dynamic Biosensors		 Proteins With a High-Throughput Conformation Biosensor Analysis of conformational changes in proteins induced by the binding of small molecules Real-time monitoring of multimerization and aggregation processes Discrimination of different ubiquitinylation states Description of high-throughput workflows with the heliX® biosensor
	10.45 <mark>7.45</mark>	Speed Networking & Morning Break
		Reinventing the face-to-face networking in the virtual world. We will pair you up with fellow attendees to break the ice and make new and lasting connections!
	11.50 <mark>8.50</mark>	Examining the Effects of Sonication on Alpha Synuclein Pre- Formed Fibrils (PFFs)
Ariel Louwrier President & CEO StressMarq Biosciences Inc.		 Alpha synuclein and tau pre-formed fibrils (PFFs) are useful tools for modelling neurodegenerative diseases. Various types can be generated with different properties PFFs need to be sonicated prior to introducing them to cellular or animal models in order to generate disease pathology. This was originally though to be because sonication reduces fibril length. Our data shows that solubility and fibril length both change with sonication. Increased solubility is more likely to account for the increased potency of oligomers and certain fibril types

🔇 +1 617 455 4188 🛛 🎯 info@hansonwade.com





Michele Vendrusco Professor & CSO Cambridge Universi Centre for Misfoldin Diseases & Wren Therapeutics	ty	 Rational Design of Conformation-Specific Antibodies Targeting Protein Aggregates Discussing why protein oligomers are challenging targets for antibody discovery Presenting a method of antibody discovery for these targets Exploring how these antibodies can be used for diagnostics and therapeutics
	12.30 <mark>9.30</mark>	Engineered Chaperone Therapeutics: Transformative Therapeutics for Repairing Protein Misfolding of Conformational Diseases
Akinori Hishiya Founder & CSO SOLA Biosciences		 SOLA is a biotherapeutics company focusing on developing transformative therapies which enable the specific protein folding for disease-causing proteins SOL-01 diminishes aggregation of mutated huntingtin proteins without affecting wild-type huntingtin proteins, and SOL-02 suppresses misfolded alpha-synuclein proteins SOLA's science team designs the technology for targeted protein folding. SOLA is looking for collaborators and partners to accelerate the therapeutic development
	12.50 <mark>9.50</mark>	Speed Networking & Lunch Break
Identifying N	ovel Therape	eutics Using Innovative Drug Discovery Approaches
Judith Frydman Professor Stanford Universit	1.50 10.50 Y	 Antiviral Approaches Targeting Proteostasis are Safe, Effective and Do Not Elicit Drug Resistance Viruses are hyper-dependent on the host proteostasis machinery This provides an opportunity to develop broad spectrum antivirals that do not elicit drug resistance
Professor		 and Do Not Elicit Drug Resistance Viruses are hyper-dependent on the host proteostasis machinery This provides an opportunity to develop broad spectrum antivirals that do

2.50 **11.50**

Cross-Learnings from Mechanisms of Action Underlying Protein Conformational Disorders

- How to evaluate the safety and tolerability of novel protein misfolding therapeutics as assessed through clinical development
- How can the commonalities in underlying molecular pathology be used to inform the development of new treatment options for protein-misfolding diseases?
- How can you leverage a clinical developmental strategy to address a range of diseases caused by protein misfolding for which no approved disease-modifying treatments currently exist?

Christopher Missling

President & CEO

Anavex Life

Sciences

3.20 **12.20**

Afternoon Networking Break





	5.30 <mark>2.30</mark>	End of Day One of Protein Misfolding Drug Discovery Summit
	5.20 <mark>2.20</mark>	Chairperson's Closing Remarks
CSO Alzheon		 Presenting a small molecule modifier of protein misfolding through a nove "enveloping MOA" Discussing how these small molecule modifiers represent a promising new class of agents for neurodegenerative disease
John Hey	4.50 1.50	Discussing ALZ-801 - A Phase 3 Ready Conformational Modifier with Disease Modifying for Alzheimer's Disease
Matthew Townsend Global Director of Proteostasis, Alzheimer's Disease AbbVie	4.20 1.20	 Using Single Particle Detection Technologies to Quantify Pathological Tau in Extracellular Vesicles & Biofluids Outlining methods development Discussing the value of exosome capture in distinguishing AD from control Comparing CSF and plasma
Robert Scannevin VP, Discovery Biology Yumanity		 Using a yeast-to-human phenotypic screening platform we recently discovered that small molecule inhibitors of stearoyl-coA-desaturase (SCI potently protect cells from α-synuclein toxicity Preclinical data confirmed that reduction of fatty-acid desaturation is correlated with protection, providing a translational pharmacodynamic marker that can be used in animals and human studies Focusing on the preclinical discovery and recent Phase Ia human clinical data from our lead SCD inhibitor, YTX-7739
	3.50 <mark>12.50</mark>	Discovery & Clinical Translation of a Small-Molecule Inhibitor of α -Synuclein Toxicity

Optimizing Preclinical Models & Technologies for Robust Translation into the Clinic

The prion-like hypothesis in Alzheimer's and Parkinson's now has a substantial body of supporting evidence. This conference addresses how pharma/biotech plan to develop new therapies with this knowledge

Matthew Townsend, Global Director of Proteostasis, Alzheimer's Disease, AbbVie

Excited to share insights into advancement of clinical findings relevant to the scientific community and the patient population affected by the respective diseases

Christopher Missling, President & CEO, Anavex Life Sciences





CONFERENCE DAY TWO THURSDAY | OCTOBER 29

9.30AM - 3.30PM EDT | 6.30AM - 12.30PM PDT

	9.00 <mark>6.00</mark>	Virtual Coffee Networking
	9.20 <mark>6.20</mark>	Chairperson's Opening Remarks
	Exploring	Different Molecular Approaches of
Targ	jeting Misfo	Ided, Oligomeric & Aggregated Proteins
Wagner Zago CSO Prothena	9.30 <mark>6.30</mark>	 Embarking on a New Era of Immunotherapy for Proteinopathi Focusing on the evidence that antibodies can reduce extracellular and intraneuronal accumulation of protein aggregates and prevent neurodegeneration Reviewing the current clinical landscape of immunotherapeutics being tested in neurodegenerative diseases
	10.00 7.00	Role of Gut Microbiota-Derived Compound(S) in A-Synuclein
Giulio Pasinetti Chair & Professor of Neurology Icahn School of Medicine at Mount Sinai		 Misfolding and C9orf72 Hexanucleotide Repeat Expansion as Novel Therapeutic in Parkinson-Plus Syndromes Learning the mechanism through which microbiome derived polyphene metabolites may attenuate seeding and a -synuclein Discussing the role of the gut-brain axis in promotion in mechanism associated to protein misfolding in models of Parkinson plus such as frontotemporal dementia, cortico-basal degeneration, etc) Discussing the potential role of gut microbiota-derived dietary polyphenolic compound to increase the likelihood of therapeutic efficacy in Parkinson-plus syndromes
Beth Hoffman Founder, President & CEO Origami Therapeutics	10.30 7.30	 Use of High Content Screening to Identify Conformation Modulators as Therapeutics for Huntington's Disease Phenotypic assays enabled identification of small molecules that preve disease-causing mutated huntingtin aggregation Deconvolution of phenotypic screening to determine mechanism of act The use of chemo-phenomics and patient-derived model systems to se and optimize leads with therapeutic potential
	11.00 <mark>8.00</mark>	Speed Networking & Morning Break Reinventing the face-to-face networking in the virtual world. We will part you up with fellow attendees to break the ice and make new and lasting connections
Highlig	ghting Differ	rent Modalities in Development for Protein
	C	Conformational Disorders
Neil Cashman CSO & Co-Founder ProMIS Neurosciences	11.30 8.30	 Precision Immunotherapies for Protein Misfolding Diseases: T ProMIS Platform Toxic, propagating misfolded proteins underlie neurodegeneration Antibodies directed against protein misfolding-selective epitopes can neutralize toxicity and propagation in disease
Gergely Tóth Founder & CEO CantaBio Pharmaceuticals	12.00 <u>9.00</u>	 Targeting the Intrinsically Disordered State of Tau & Alpha-Synuclein By Small Molecules as a Therapeutic Strategy for Alzheimer's & Parkinson's Disease Intrinsically disordered tau and alpha-synuclein are viable receptors of drug-like small molecules Application of computer-aided structure based and biophysical screen paradigms resulted in the discovery of novel small molecule ligands to and alpha-synuclein Targeting the monomeric state of intrinsically disordered proteins by small molecule to reduce their misfolding and aggregation is a feasible therapeutic approach







	12.30 <mark>9.30</mark>	Speed Networking & Lunch Break
	1.30 10.30	Translating Exciting Science into Clinical Success in Parkinson's Disease; Examples of Synuclein & Glucocerebrosidase Targeting
Peter Lansbury CSO		 Biomarkers for drug action in the brain are considered to be necessary for big pharma - are they really?
Lysosomal Therapeutics		 Addressing how selection of patients for early trials is the most important issue
-		 Discussing why the connection between synuclein and Parkinson's disease is not as clear as you have been led to believe
00 11 00 Banal Di	cussion. Conduc	ting a Stratogic Anglycic of Brotoin Micfolding Thorapoutics
What keyWhat cha accelerat	learnings can be a nge do you want to e robust candidates	
 What key What cha accelerat Where are progress? 	learnings can be ap inge do you want to e robust candidate: e the key opportuni	pplied from clinical successful companies in this space? o see in this space from both large pharma and biotech companies to s into the clinic? ties for money flow, partnerships and collaborations to accelerate scientific
 What key What cha accelerat Where are progress? What is the 	learnings can be ap inge do you want to e robust candidates e the key opportuni ne market opportun	pplied from clinical successful companies in this space? o see in this space from both large pharma and biotech companies to s into the clinic?

▲ We now face a critical transition in our understanding of intrinsically disordered protein (IDP) domains in eukaryotic cells, from how they process information to their impact on disease. This transition must be catalyzed by industrial and academic collaboration if we are to successfully address the growing threat of protein misfolding diseases as our population ages ■ David Lynn, HHMI Professor, Emory University





PARTNER WITH US

As we continue to adapt considering the global public health situation, the **Digital Protein Misfolding Drug Discovery Summit** offers a unique opportunity to continue collaborating with decision makers in the field. We'll work with you to build bespoke partnerships to ensure you meet your 2020 business objectives.

Below are some of the unique opportunities available through the digital summit.



Secure a virtual exhibition booth to **showcase your expertise and educate the industry on how you can support their R&D**



Leverage targeted online networking to **facilitate lead generation and build new relationships with senior level decision makers from leading pharma and biotech companies**



Secure a branding or speaking opportunity to **demonstrate your thought leadership, drive your brand exposure and differentiate yourself from competitors**



Innovation Partner

StressMarq Biosciences is a research reagents company manufacturing antibodies, proteins, ELISA kits, and small molecules. It is currently the only company worldwide that manufactures active recombinant alpha synuclein and tau fibrillar "seeds" that can generate Lewy body and tau pathologies, respectively. These have become increasingly popular in generating neurodegenerative disease models. Additionally, StressMarq has pursued patent protection for an antibody with alpha synuclein aggregation neutralization capability, resulting in a therapeutic candidate for Parkinson's and Alzheimer's. **www.stressmarq.com**



Innovation Partner

Dynamic Biosensors is a provider of instruments, consumables, and services in the field of analytical systems for the characterization of biomolecules and molecular interactions. We are headquartered in Martinsried, south of Munich / Germany, a vital center of Europe's biotechnology industry. Dynamic Biosensors commercializes switchSENSE® technology, a groundbreaking platform technology for the analysis of biomolecules with applications in R&D and drug development. The switchSENSE® technology is protected worldwide and only available through Dynamic Biosensors. **www.dynamic-biosensors.com**



Innovation Partner

SOLA is a biotherapeutics company focusing on developing transformative therapies to treat protein misfolding diseases. SOLA's technology is designed to harness the power of a patient's own chaperones to repair disease-causing proteins. Our innovative engineered chaperone technology enables the repairing of misfolded proteins which cause devastating neurogenerative diseases such as Huntington and Parkinson's diseases. **www.sola-bio.com**





Jacob Roberts-Kendall Partnerships Director Tel: +1 617 455 4188 Email: sponsor@hansonwade.com







Protein Misfolding Drug Discovery Summit

October 27-29, 2020 | Digital Event

READY TO REGISTER?

3 EASY WAYS TO BOOK



www.protein-misfolding.com

Tel: +1 617 455 4188

Email: register@hansonwade.com



SAVE valuable time and resources by learning how the leading companies in the space are advancing their pipeline of therapeutics targeting misfolded and oligomeric proteins



GAIN first-hand insights on challenges and strategies on how to robustly translate promising protein misfolding targeted therapeutics into clinical development and increase your success rate



FORM lasting connections by engaging directly with colleagues from the leading pharma and biotech companies actively developing protein misfolding targeted therapeutics and seeking the best solutions, in an intimate environment

Please select appropriate price when booking. Bookings are subject to approval.

Industry Pricing	Register & Pay by Friday, July 31 (SAVE UP TO \$600)	Standard Pricing
Conference + 2 Workshops	\$2,247	\$2,847
Conference + 1 Workshop	\$1,998	\$2,448
Conference Only	\$1,749	\$2,049
Workshop Only	\$349	\$499
Academic Pricing	Register & Pay by Friday, July 31 (SAVE UP TO \$600)	Standard Pricing
Academic Pricing Conference + 2 Workshops		Standard Pricing \$2,347
	(SAVE UP TO \$600)	
Conference + 2 Workshops	(SAVE UP TO \$600) \$1,747	\$2,347

*Please note: If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge you will have the option to provide your VAT number and the charge will be automatically deducted at checkout. Visit the website for more details.

Team Discounts

- 10% discount 3 delegates
- 15% discount 4 delegates
- 20% discount 5 + delegates

Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to boostpone or cancel an event, to change the location or alter the adversized speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event. for any reason and including causes beyond its control including without limitation, cats of God, natural disasters, sabocage, accident, trade or industrial disputes, terrorism or hostilities. Data Pratection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London ECTY OTH

+1 617 455 4188 info@hansonwade.com
www.protein-misfolding.com

